Insights

Loading spinner
Gathering insights about Apollomics

Apollomics Tech Stack

Apollomics uses 8 technology products and services including Cloudinary, jQuery CDN, Drupal, and more. Explore Apollomics's tech stack below.

  • Cloudinary
    Content Delivery Network
  • jQuery CDN
    Content Delivery Network
  • Drupal
    Content Management System
  • Font Awesome
    Font Scripts
  • jQuery
    Javascript Libraries
  • Module Federation
    Miscellaneous
  • Popper
    Miscellaneous
  • Google Tag Manager
    Tag Management

Media & News

Apollomics's Email Address Formats

Apollomics uses at least 1 format(s):
Apollomics Email FormatsExamplePercentage
First.Last@apollomicsinc.comJohn.Doe@apollomicsinc.com
49%
First.Middle@apollomicsinc.comJohn.Michael@apollomicsinc.com
1%
Fir.Last@apollomicsinc.comJoh.Doe@apollomicsinc.com
1%
First.Last@apollomicsinc.comJohn.Doe@apollomicsinc.com
49%

Frequently Asked Questions

Where is Apollomics's headquarters located?

Minus sign iconPlus sign icon
Apollomics's main headquarters is located at 989 E Hillsdale Blvd Suite 220 Foster City, California 94588 US. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is Apollomics's stock symbol?

Minus sign iconPlus sign icon
Apollomics is a publicly traded company; the company's stock symbol is APLMW.

What is Apollomics's official website and social media links?

Minus sign iconPlus sign icon
Apollomics's official website is apollomicsinc.com and has social profiles on LinkedIn.

How much revenue does Apollomics generate?

Minus sign iconPlus sign icon
As of September 2024, Apollomics's annual revenue reached $15M.

What is Apollomics's SIC code NAICS code?

Minus sign iconPlus sign icon
Apollomics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Apollomics have currently?

Minus sign iconPlus sign icon
As of September 2024, Apollomics has approximately 51 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Financial Officer: M. P.Chief Financial Officer: W. C.Chief Scientific Office, General Manger In China Sites: J. W.. Explore Apollomics's employee directory with LeadIQ.

What industry does Apollomics belong to?

Minus sign iconPlus sign icon
Apollomics operates in the Biotechnology Research industry.

What technology does Apollomics use?

Minus sign iconPlus sign icon
Apollomics's tech stack includes CloudinaryjQuery CDNDrupalFont AwesomejQueryModule FederationPopperGoogle Tag Manager.

What is Apollomics's email format?

Minus sign iconPlus sign icon
Apollomics's email format typically follows the pattern of . Find more Apollomics email formats with LeadIQ.

How much funding has Apollomics raised to date?

Minus sign iconPlus sign icon
As of September 2024, Apollomics has raised $24M in funding. The last funding round occurred on Mar 30, 2023 for $24M.

When was Apollomics founded?

Minus sign iconPlus sign icon
Apollomics was founded in 2015.
Apollomics

Apollomics

Biotechnology ResearchCalifornia, United States51-200 Employees

Apollomics is an innovative biotechnology company committed to the discovery and development of oncology combination therapies. With operations in both the U.S. and China, we believe we are well positioned to unlock synergies by leveraging the strengths of partnerships with other biotechnology companies in the East and the West.

Since our founding in 2015, under the leadership of our experienced management team with in-depth knowledge and expertise of the evolving cancer treatment landscape, we have built a pipeline of ten (10) drug candidates across 12 programs that focus on oncology, of which five (5) drug candidates are at clinical stage. The drug candidates in our existing pipeline can be categorized into three (3) groups based on their mechanisms of action, each of which contains drug candidates at different stages of development. The first group is “tumor inhibitors”, which consists of four (4) small molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells, one of which is our Core Product, a c-Met inhibitor. The second group is “anti-cancer enhancers”, which could enhance the anti-cancer effects of other treatments. This group comprises two (2) antagonists against a cell adhesion receptor, which are being developed as adjuncts to chemotherapy. The last group is “immuno-oncology drugs”, which take the advantage of the body’s immune system to fight cancer. This group comprises four (4) drug candidates, including mono-specific and bi-specific antibodies that releases the natural brakes of immune response against cancer cells, as well as a novel cancer vaccine.

Having three (3) groups of drug candidates with different mechanisms of action would enable us to develop potential synergistic combination therapies that address unmet needs in cancer treatment.

To learn more about Apollomics, visit our website at https://www.apollomicsinc.com/

Section iconCompany Overview

Headquarters
989 E Hillsdale Blvd Suite 220 Foster City, California 94588 US
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
APLMW
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
51-200

Section iconFunding & Financials

  • $24M

    Apollomics has raised a total of $24M of funding over 5 rounds. Their latest funding round was raised on Mar 30, 2023 in the amount of $24M.

  • $10M$50M

    Apollomics's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $24M

    Apollomics has raised a total of $24M of funding over 5 rounds. Their latest funding round was raised on Mar 30, 2023 in the amount of $24M.

  • $10M$50M

    Apollomics's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.